KLDO

0.00010.00%
MA

Mark A. Wingertzahn

Senior VP of R&D and Head of Development

Dr. Mark A. Wingertzahn, Ph.D., served as Senior Vice President of Clinical Development & Medical Affairs at Invivyd, Inc. since 2024 until March 2026. He serves as Member of Advisory Board at Group K Diagnostics, Inc. He serves as a Chief Scientific Officer at Wesana Health Holdings Inc. (formerly known as Made Therapeutics, Inc.) since May 2021 and served as its Chief Strategy Officer until May 2021. He serves as Senior Vice President of R&D and Head of Development at Kaleido Biosciences, Inc. since 2021. Dr. Wingertzahn joined Kaleido in May 2019. He is responsible for oversight and strategic direction of all global Clinical Development activities at Kaleido. He has experience in non-clinical and clinical development in Pharma, Biotech as well as the Consumer Healthcare areas. Most recently, He was Head of Clinical Development at GSK and prior to that was the Head of Global Clinical Research at Pfizer Consumer Health. Prior to his tenure at Pfizer, Dr. Mark took on roles of increasing complexity in the areas Medical and Scientific Affairs and Clinical Development where his teams achieved multiple U.S. and Ex-U.S. drug approvals for prescription modalities to treat CNS, endocrinologic, respiratory, cardiovascular, GI, pain disorders as well as post-surgical wound healing. Previously, he worked at Nycomed (formerly Altana Pharma) and in academia serving as an Instructor of Pediatrics at NYU School of Medicine and Associate Professor of Life Sciences & Allied Health at the New York Institute of Technology College of Osteopathic Medicine. He completed his Ph.D. in pharmacology at St. John’s University and his post-doc in Perinatal Medicine at NYU School of Medicine.

Positions